Published in Nat Nanotechnol on April 08, 2012
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst (2013) 1.75
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano (2012) 1.62
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A (2012) 1.51
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med (2013) 1.44
Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics (2013) 1.44
The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng (2014) 1.40
Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res (2013) 1.34
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A (2015) 1.31
Benefits of vascular normalization are dose and time dependent--letter. Cancer Res (2013) 1.22
A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun (2014) 1.17
Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat Commun (2013) 1.16
Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. Biomaterials (2012) 1.13
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity (2016) 1.11
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. J Natl Cancer Inst (2015) 1.08
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
(18)F-labeled-bioorthogonal liposomes for in vivo targeting. Bioconjug Chem (2013) 1.05
Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano (2014) 1.04
Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb) (2014) 1.02
Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells. ACS Nano (2014) 1.01
Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol (2013) 0.99
Photoswitchable nanoparticles for in vivo cancer chemotherapy. Proc Natl Acad Sci U S A (2013) 0.99
A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J Nucl Med (2014) 0.99
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem (2013) 0.98
Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci U S A (2014) 0.98
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget (2016) 0.96
The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res (2014) 0.95
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther (2013) 0.95
Cationic nanoparticles have superior transvascular flux into solid tumors: insights from a mathematical model. Ann Biomed Eng (2012) 0.95
Modeling of nanotherapeutics delivery based on tumor perfusion. New J Phys (2013) 0.94
Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol (2014) 0.93
Blood-stable, tumor-adaptable disulfide bonded mPEG-(Cys)4-PDLLA micelles for chemotherapy. Biomaterials (2012) 0.93
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano (2014) 0.92
Cellular and physiological roles for phospholipase D1 in cancer. J Biol Chem (2014) 0.91
H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc Natl Acad Sci U S A (2014) 0.90
Improving chemoradiotherapy with nanoparticle therapeutics. Transl Cancer Res (2013) 0.89
Challenges and opportunities in the advancement of nanomedicines. J Control Release (2012) 0.89
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Theranostics (2015) 0.89
Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PLoS One (2015) 0.89
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci U S A (2016) 0.87
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Sci Rep (2015) 0.87
Numerical Modeling of Interstitial Fluid Flow Coupled with Blood Flow through a Remodeled Solid Tumor Microvascular Network. PLoS One (2013) 0.87
Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci U S A (2015) 0.87
Stress-mediated progression of solid tumors: effect of mechanical stress on tissue oxygenation, cancer cell proliferation, and drug delivery. Biomech Model Mechanobiol (2015) 0.87
Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. Biomacromolecules (2014) 0.87
Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy. Front Oncol (2015) 0.86
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res (2014) 0.86
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep (2015) 0.85
Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors. J Biol Eng (2014) 0.84
Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport. Nanomedicine (2013) 0.84
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem (2014) 0.84
Plasmonic photothermal therapy increases the tumor mass penetration of HPMA copolymers. J Control Release (2012) 0.84
Interstitial fluid flow in cancer: implications for disease progression and treatment. Cancer Manag Res (2014) 0.84
Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches. Adv Funct Mater (2016) 0.84
Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget (2014) 0.84
Spatial charge configuration regulates nanoparticle transport and binding behavior in vivo. Angew Chem Int Ed Engl (2012) 0.84
Potential use of folate-appended methyl-β-cyclodextrin as an anticancer agent. Sci Rep (2013) 0.83
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Control Release (2015) 0.83
Reversibly crosslinked nanocarriers for on-demand drug delivery in cancer treatment. Ther Deliv (2012) 0.83
Nanogel Carrier Design for Targeted Drug Delivery. J Mater Chem B Mater Biol Med (2014) 0.83
Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. Int J Clin Exp Med (2015) 0.83
Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J Control Release (2016) 0.82
R-Ras protein inhibits autophosphorylation of vascular endothelial growth factor receptor 2 in endothelial cells and suppresses receptor activation in tumor vasculature. J Biol Chem (2015) 0.82
Intravital imaging of mouse colonic adenoma using MMP-based molecular probes with multi-channel fluorescence endoscopy. Biomed Opt Express (2014) 0.81
Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. Bioconjug Chem (2014) 0.81
Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction. Acta Biomater (2014) 0.81
Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene (2015) 0.81
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery. Int J Cancer (2013) 0.80
Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT Pharmacometrics Syst Pharmacol (2012) 0.80
Quantifying uncertainties in the microvascular transport of nanoparticles. Biomech Model Mechanobiol (2013) 0.80
Quantitative Fluorescent Microscopy to Measure Vascular Pore Sizes in Primary and Metastatic Brain Tumors. Cancer Res (2016) 0.80
Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. JCI Insight (2016) 0.79
The solid mechanics of cancer and strategies for improved therapy. J Biomech Eng (2016) 0.79
Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors. Ann Biomed Eng (2015) 0.79
Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. Transl Oncol (2014) 0.79
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release (2015) 0.79
Fibroblast Growth Factor 9 Imparts Hierarchy and Vasoreactivity to the Microcirculation of Renal Tumors and Suppresses Metastases. J Biol Chem (2015) 0.79
Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects. PLoS One (2013) 0.79
Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater (2016) 0.78
Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner. Sci Rep (2017) 0.78
Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release (2014) 0.78
Preparation of compact biocompatible quantum dots using multicoordinating molecular-scale ligands based on a zwitterionic hydrophilic motif and lipoic acid anchors. Nat Protoc (2015) 0.78
Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett (2015) 0.78
Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. J Control Release (2014) 0.78
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res (1988) 3.37
VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol (2007) 2.74
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng (2011) 2.17
Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res (2010) 2.11
Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 2.00
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 1.84
Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation (1997) 1.71
Scale-invariant behavior and vascular network formation in normal and tumor tissue. Phys Rev Lett (1995) 1.67
Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A (2011) 1.54
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res (2006) 1.39
Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res (1997) 1.38
A model of fluid flow in solid tumors. Ann Biomed Eng (2003) 1.17
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
Predicting protein structures with a multiplayer online game. Nature (2010) 9.95
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Crystal structure of a monomeric retroviral protease solved by protein folding game players. Nat Struct Mol Biol (2011) 5.02
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging (2003) 4.01
Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol (2006) 3.98
Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer (2002) 3.96
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell (2009) 3.37
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J (2002) 3.25
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 3.13
The role of nitric oxide in tumour progression. Nat Rev Cancer (2006) 3.08
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Compact biocompatible quantum dots functionalized for cellular imaging. J Am Chem Soc (2008) 2.92
Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol (2010) 2.85
Fluorescence resonance energy transfer between quantum dot donors and dye-labeled protein acceptors. J Am Chem Soc (2004) 2.72
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat Methods (2008) 2.68
Oligomeric ligands for luminescent and stable nanocrystal quantum dots. J Am Chem Soc (2003) 2.68
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 2.67
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Size series of small indium arsenide-zinc selenide core-shell nanocrystals and their application to in vivo imaging. J Am Chem Soc (2006) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A (2010) 2.62
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc (2007) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg (2005) 2.52
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
Retracted Dance reveals symmetry especially in young men. Nature (2005) 2.41
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 2.29